Detalles de la búsqueda
1.
Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.
Am J Hematol
; 98(5): 703-711, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36710399
2.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Blood
; 131(8): 855-863, 2018 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29203585
3.
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Blood
; 129(24): 3165-3174, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28336527
4.
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Blood
; 129(24): 3175-3183, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28468797
5.
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Oncology
; 96(4): 217-222, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30844808
6.
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Breast Cancer Res Treat
; 171(1): 111-120, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29744674
7.
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Future Oncol
; 12(12): 1469-81, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26997579
8.
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
Support Care Cancer
; 24(4): 1517-25, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26370220
9.
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
Support Care Cancer
; 23(3): 723-32, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25179689
10.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood
; 119(24): 5661-70, 2012 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22555973
11.
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Lancet Oncol
; 14(4): 335-45, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23499390
12.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol
; 11(1): e15-e26, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38135371
13.
Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
Cancer Immunol Immunother
; 62(9): 1511-20, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23877659
14.
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
J Immunother Cancer
; 10(3)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35332062
15.
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 27(13): 3630-3640, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33820783
16.
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Cancer Discov
; 11(8): 1996-2013, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33707233
17.
TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.
J Vasc Interv Radiol
; 21(12): 1852-8, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21111365
18.
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Clin Pharmacokinet
; 48(3): 199-209, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19385713
19.
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Clin Cancer Res
; 14(9): 2756-62, 2008 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18451242
20.
Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.
J Comp Eff Res
; 8(9): 657-670, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31070042